Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer

Exclusion Criteria

• •Previous anticancer therapy for the pancreatic adenocarcinoma;
• •Biliary obstruction without endoscopic biliary drainage;
• •Any contre-indication for surgery;
• •Prior malignancy (except non-melanoma skin cancer, and in situ carcinoma of the uterine cervix treated with a curative intent and any other tumor in complete remission with a disease-free interval \> 3 years);
• •Uncontrolled congestive heart failure or angina pectoris, myocardial infarction within 1 year prior to study entry, uncontrolled hypertension (systolic pressure \> 160 mm or diastolic pressure \> 100 mm under well conducted antihypertensive treatment), QT prolongation;
• •Major uncontrolled infection;
• •Severe hepatic impairment;
• •Any medical, psychological, or social condition, which, in the opinion of the investigator, could hamper patient's compliance to the study protocol and/or assessment/interpretation of the data;
• •Pregnant or lactating women, or patients of both genders with procreative potential not using adequate contraceptive methods;
• •Patients receiving or having received any investigational treatment within 4 weeks prior to study entry, or participating to another clinical study; patients previously enrolled into this study.